Belluscura plc

Founded in 2016, Belluscura plc is a London-based medical technology company that develops innovative portable oxygen concentrators aimed at improving the quality of life for individuals requiring supplemental oxygen therapy. Belluscura plc specializes in creating portable oxygen concentrators. The company was founded in London, UK, and has undergone strategic developments since its inception. The CEO, Bob Rauker, leads the company, which has successfully raised a total of GBP 1.

150 mn through its most recent funding round, Series B, on November 22, 2024. The firm has completed 4 deals to date and currently holds a valuation of GBP 3. 161 mn. Belluscura specializes in the development and manufacturing of innovative portable oxygen concentrators, primarily focusing on enhancing the quality of life for individuals who require supplemental oxygen therapy.

Their flagship products, the DISCOV-R™ and X-PLOR®, utilize patented ModulAir™ and Airgonomical™ technologies to deliver lightweight, compact solutions that maximize oxygen output while minimizing weight—both units weigh less than 6. 5 lbs. These devices are designed for a diverse clientele, including patients with chronic respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD) and other individuals needing oxygen therapy for varying durations. By prioritizing user-friendly design and portability, Belluscura caters to markets across North America and Europe, ensuring that end users can engage in their daily activities without the constraints typically associated with traditional oxygen tanks.

Belluscura generates revenue primarily through the direct sale of its portable oxygen concentrators and associated accessories, targeting both individual consumers and healthcare providers. Transactions typically occur via direct-to-consumer sales and partnerships with durable medical equipment (DME) providers and retailers. The company's products, such as the X-PLOR® and DISCOV-R™, achieved a revenue of GBP 825,409 in 2023. Revenue is supplemented through the sale of various accessories designed to support the use and maintenance of their oxygen concentrators.

The company reported an EBITDA of GBP -14,235,699 in the same year, reflecting its current operational status within the healthcare equipment market. In November 2024, Belluscura plc raised USD 4 million in venture debt funding from new investor Sallyport Commercial Finance. The company will use the funding to support the launch of its DISCOV-R portable oxygen concentrator, covering accounts receivable, purchase orders, inventory, and cash flow to prepare for full production in early 2025. Belluscura is also targeting expansion into new markets, focusing on increasing its presence in North America and Europe by 2025.